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Abst rac t
Introdcution: Through interaction with receptors TNFR1 and TNFR2, TNF-α activates a signal path, which exacer-
bates an inflammatory process, constituting an inseparable element of psoriasis. 
Aim: To evaluate changes in the expression of TNF-α, TNFR1, TNFR2 during the 4-year-long adalimumab therapy 
in psoriatic patients, searching for the correlation between molecular and clinical markers. In addition, the role of 
miRNAs was analysed. 
Material and methods: Whole blood and serum samples of psoriatic patients treated with adalimumab constituted 
material for the study. Changes in the expression of TNF-α and its receptors were evaluated with the use of the 
RTqPCR method and MALDI ToF mass spectroscopy, PASI, BSA, DAS28 indexes were used for the clinical analysis of 
the patients, while the role of miRNA molecules was determined basing on microrna.org database.
Results: Different TNF-α expression patterns were determined in patients with observed resistance to the medicine. 
We found that there is a correlation between the molecular markers of an inflammatory process and the clinical 
indexes. The bioinformatic analysis indicates the potential role of miRNAs in the regulation of expression of the 
analysed genes. Changes in the profile of TNF-α during adalimumab therapy are significantly determined by the 
individual variability and susceptibility to the biological medicine or its loss. 
Conclusions: TNF-α seems to be a useful marker to evaluate the efficacy of therapy and occurring resistance to 
the medicine. A complex mechanism for the regulation of the analysed gene expression was underlined, which 
involved the potential role of miRNAs.
Key words: tumor necrosis factor α, treatment personalisation, miRNA, anti-TNF therapy, psoriasis.
Introduction
The tumour necrosis factor α (TNF-α) belongs to a su-
perfamily of proteins. It is characterised by proinflam-
matory properties and plays an important role in the im-
munologic response of human body [1–3]. It is generated 
by various types of cells, mainly the macrophages, mono-
cytes, lymphocytes T and B, and synoviocytes. Two types 
of receptors for TNF-α are distinguished: TNFR1 and 
TNFR2 [2]. The first one is expressed in almost all nucle-
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ated cells of human body, whereas the second receptor 
is expressed in fibroblasts, endothelial cells, lymphocytes, 
macrophages [1–5]. An interaction of TNF-α with recep-
tors activates signalling cascades, the programmed cell 
death is activated when the ligand binds with TNFR1. In 
turn, receptor TNFR2 activates the cascade of the NF-kB 
path, inducing an inflammatory reaction in the cell [6]. 
Gene expression is strictly regulated on various levels, 
one of them being an epigenetic mechanism of the neg-
ative regulation of transcription by microRNA (miRNA) 
molecules. MiRNAs are short, about 23-nucleotide, non-
coding fragments of RNA, regulating the expression 
of about 1/3 of all human genes [7]. The role of miRNAs 
in the regulation of gene expression was studied by us 
with reference to the histaminergic role [8]. The role 
of these regulatory molecules is also emphasised in pso-
riasis [9, 10].
Psoriasis is a chronic, inflammatory skin disorder with 
complex immunopathogenesis [11]. TNF-α and the follow-
ing interleukins (IL) play a significant role in psoriasis: 
IL-1, IL-6, IL-8, IL-12, IL-23. Their secretion is excessive and 
has an uncontrollable nature. TNF-α in psoriasis causes 
keratinocytes activation and their excessive prolifera-
tion. It is also responsible for an increased proliferation of 
T and B lymphocytes and their differentiation [11]. 
The anti-TNF therapy is one of the most efficient 
methods for treatment of proinflammatory diseases. 
Unfortunately, it also involves numerous undesirable ef-
fects [12, 13] and the occurrence of lost response to the 
medicine [13, 14]. 
Adalimumab is a fully-humanised human monoclonal 
antibody, showing ability to neutralise the TNF-α, either 
in its membrane-related and soluble form, thus interrupt-
ing the signal path activated by the said cytokine. The 
efficacy of treatment measured with the use of PASI-75 
index is over 60%, in case of therapy lasting more than 
60 weeks [15, 16].
Aim
The aim of the study is to evaluate the expression of 
TNF-α and its receptors TNFR1 and TNFR2, and the role 
of the epigenetic mechanism – the miRNA molecules – 
in the regulation of expression of the analysed genes in 
patients treated with anti-TNF adalimumab during the 
4-year-long observation. The correlation between mo-
lecular markers and disease progression indexes or its 
absence was also evaluated.
Material and methods
Whole blood and serum of patients treated with 
adalimumab (2 women – patients A and B, and 5 men 
– patients C, D, E, F, G), aged 47.2 ±9.86 years, with diag-
nosed psoriatic arthritis, who gave their informed con-
sent to the study, constituted the material used for the 
tests. Patient A was monitored within the dose range: 
11–94 (42 months), B – 23–103 (39 months), C – 25–96 
(42 months), D – 6–94 (39 months), and E – 31–105 (36 
months). The monitoring time of patients F (15 months) 
and G (3 months) was shorter than the time of moni-
toring the other patients due to the fact that patients 
F and G lost their response to the adalimumab therapy. 
The clinical and molecular characteristics of those 2 pa-
tients during their adalimumab therapy were only taken 
into account. The material used for the study was taken 
from patients every 12 weeks. The blood was taken be-
fore the administration of a next dose of the medicine 
and 2 h after its administration, which constituted one 
monitoring session for each patient. Each patient was 
given adalimumab at a concentration of 40 mg every 
2 weeks. Molecular and clinical assessment was per-
formed every 12 weeks.
The control group consisted of 20 people (9 women 
and 11 men), aged 46 ±10 years, who gave their voluntary 
consent to the study by signing the informed consent 
forms. The volunteers were healthy persons, who did not 
suffer from psoriasis or other skin diseases and who had 
not used any corticosteroids during the 3 months preced-
ing their participation in the research project. 
The first stage of the molecular analysis involved 
isolation of total RNA from the whole blood with the 
use of FENOZOL reagent (A&A Biotechnology, Gdańsk, 
Poland), according to the guidelines included in the pro-
tocol. Extracts of nucleic acid were then quantitatively 
assessed through electrophoresis in 0.8% agarose gel, 
and also qualitatively by means of spectrophotometry 
(GeneQuant II, Pharmacia Biotech).
The next stage of the molecular analysis involved the 
qualitative amplification reaction with reverse transcrip-
tion (RTqPCR) for mRNA for the following genes: TNF-α, 
TNFR1, TNFR2 in the presence of β-actin (ACTB), as a con-
trol of endogenous reactions. The reaction was conducted 
with the use of pairs of starters specific for the sequence 
of each tested gene. Oligonucleotide sequences of start-
ers used for gene amplification: TNF-α (forward: 5’- 
CTCAAGCTGAGGG GCAGCTCC-3’, reverse: 5’-TGGGTGAG-
GAGCACATGGGTG-3’), TNFR1 (forward: 5’-CACCACAGT-
GCTG TTGCCCCT-3’, reverse 5’-TGGAGTGGGACTGAAGCTT 
GGG-3’), TNFR2 (forward 5’-AGTATGGCCCCAGGGGCAGTA-
CA-3’, reverse 5’-TCTCTCTGCAGGCACAAGGGCTT-3’), ACTB 
(forward 5’-TCACCCACACTGTGCC CATCTACGA-3’, reverse 
5’-CAGCGGAACCGCTCATTGCCAATGG-3’). The RT-qPCR re-
action was conducted with the use of the Opticon™ DNA 
Engine Sequence Detector (MJ Research Inc., Watertown, 
MA, USA), with the use of the SYBR Green Quantitect RT-
PCR Reagent Kit (Qiagen, Valencia, CA, USA), according 
to the producer’s recommendations. The thermal profile 
of the reaction was as follows: reverse transcription: 
50°C for 30 min, polymerase activation: 95°C for 15 min, 
40 cycles composed of the following stages: denatur-
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ation: 94°C for 15 s, starters activation: 53.3°C for 30 s, 
prolongation: 72°C for 45 s.
For the detection of the TNF cytokine in the serum, 
the MALDI ToF mass spectroscopy was used, supported 
by a matrix due to an exceptionally smooth ionisation. It 
excludes the possible damage of the analysed proteins. 
The MALDI-ToF2-MS2 AXIMA Performance spectrom-
eter (matrix assisted laser desorption ionisation – time-
of-flight mass spectrometry) was used for the analysis 
(Shimadzu; Kyoto, Japan). The analysis was performed 
in the linear and reflectron modes, with the accelerating 
voltage of 20 kV. The spectrometer was calibrated with 
the use of a standard ProteoMass Peptide MALDI-MS 
Calibration Kit (Sigma-Aldrich, St. Louis, MO, USA). The 
2,5-dihydroxybenzoic acid was used as a matrix (Sigma-
Aldrich). The samples were mixed with a relevant matrix 
1 : 1, and then placed on an analytic table, in the amount 
of 1.5 μl per measuring point on a graphite base in order 
to facilitate ionisation, thanks to quick rupture of the Van 
der Waals bonds. Each sample was analysed thrice in or-
der to minimise the device error. Acquired mass spec-
tra were analysed with the use of MALDI - MS software 
(Shimadzu Biotech Launchpad 2. 9 3 20110624). Prior to 
the commencement of the analysis involving the samples 
used for the study, the mass spectrum of the TNF stan-
dard was characterised with the use of MALDI ToF mass 
spectrometry, which allowed to select a relevant column 
for the gel and liquid chromatograph.
Basing on the bioinformatic databases (www.mi-
crorna.org), potential miRNAs were selected which could 
regulate the expression of analysed transcripts. The mi-
Randa-mirSVR algorithm, constituting a combination of 
the miRanda and mirSVR procedures, was used to find 
the relevant miRNA molecules. By using this algorithm, it 
is possible to select a target mRNA for a relevant miRNA 
(miRanda) molecule and determine a correlation be-
tween them (mirSVR). The analysis is performed on the 
basis of the following: a seedmatch, conservativeness, free 
enthalpy and the availability of sequence of the selected 
miRNA molecule. 
Consent of the Bioethics Commission of the Medical 
University of Silesia in Katowice/Poland no. KNW/0022/
KB1/59/I/13/14.
Statistical analysis
The statistical analysis was performed with the use 
of Statistica 12.0 PL software (StatSoft, Tulsa, Oklahoma, 
USA), assuming the statistical gravity factor p < 0.05. We 
searched for the Spearman’s rank correlation between 
the TNF-α expression profile and the clinical parameters 
(PASI, BSA, DAS28) and between each of these for each 
patient. The possible correlation between expressions of 
the three genes analysed in this study for each patient 
was also assessed.
Results 
The transcription activity of the genes under study 
was presented as the number of mRNA copies of the 
gene: TNF-α, TNFR1, TNFR2, converted into 1 μg of total 
RNA.
Changes in the expression profiles of mRNA and se-
lected clinical parameters (PASI, DAS28, BSA) in each pa-
tient during the 4-year-long observations were presented 
in Table 1. Due to a vast amount of data, Table 1 includes 
only the most significant data. 
The transcription activity of genes in the form of the 
numbers of transcript copies/1 μg of total RNA (mean ± 
standard deviation) was determined in comparison to 
the control group, composed of healthy volunteers: TNF-α 
(1149048 ±1554419), TNFR1 (547826 ±777004), TNFR2 
(1037 ±1731).
When making a general comparison, it may be noted 
that in the study group, the TNFR1 expression is lower than 
in the control group, however, the TNFR2 expression in the 
group treated with adalimumab is higher than in the group 
composed of healthy volunteers. A higher expression of 
TNF-α is also observed in the group treated with the medi-
cine, when compared with the control group. 
Expression profiles of TNF-α and its receptors were 
evaluated during the therapy for each patient individu-
ally. In general, the period during which the changes in 
the transcription activity of analysed genes were moni-
tored corresponds to 15 or 16 monitoring sessions, during 
the period of 4 years; only in case of patient E, the ther-
apy monitoring time for the needs of the study covered 
13 monitoring sessions. For patients F and G, the changes 
in the transcription activity of analysed genes and the 
clinical characteristics were presented only during the 
adalimumab therapy. Then, these patients proceeded to 
be treated with etanercept. 
When comparing the TNF-α expression in the con-
trol group and the group under study, a higher expres-
sion of the transcript may be observed in the control 
group. The situation is similar in case of TNFR1. In turn, 
in case of TNFR2, some patients (A, B, C, F, G) generally 
show a higher expression of this gene when compared 
with the control group, whereas in patients D and E, the 
TNFR2 transcript activity is lower than in the control 
group, except for some rare exceptions.
As far as patient A is concerned, there occurs no regu-
larity in TNF-α expression concerning a lower expression 
after administration of the next dose of the medicine. 
Most often, 2 h after administration of the next dose of 
medicine, an increased transcription activity of the ana-
lysed gene may be observed, when compared with the 
expression measured in time before drug administration. 
Nevertheless, the level of TNF-α expression during the 6th 
monitoring session after administration of the medicine to 
patient A is zero. Such level of expression lasts for the next 
two (7th and 8th) monitoring sessions, either before and after 
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medicine administration. Additionally, during these two pe-
riods, apart from improved molecular parameters, improve-
ment in the clinical condition can also be observed, which 
is confirmed by results of clinical parameters. Moreover, 
immediately after these drug administrations, a situation 
may be observed in which TNF-α expression before drug 
administration is higher than after it. Additionally, during 
the observation at the 13th monitoring session a clinical 
improvement was ascertained, which is confirmed by the 
obtained result of expressions of the analysed three tran-
scripts. With reference to receptor expressions, a greater 
number of transcripts of the 2nd receptor is observed when 
compared with the 1st receptor during the first and last pe-
riod of the patient’s observations, whereas between them 
(9th–12th monitoring sessions), the situation is opposite to 
the one described.
Table 1. The most significant data of molecular and clinical characteristics of patients A-G treated with adalimumab
Monitoring mRNA [copy/µg RNA] Clinical parameters
TNF-α TNFR1 TNFR2 PASI BSA DAS28
Patient A:
 I 0 0 0 10.4 25 3.02
 IV 8610 7287 2279333 9 16 2.44
 VIII 0 0 0 3 15 4.05
 XII 28267 31422 39 7 17 3.23
 XVI 28 0 168 5 9 3.84
Patient B:
 I 0 0 0 4 21 2.48
 IV 0 0 176519 4.8 4 3.09
 VIII 37824 76784 75 2 8 3.6
 XV 358 0 1746 15 15 4.29 
Patient C:
 I 10 0 0 18 31 2.62
 VII 40595153 0 189121 5 10 3.09
 XIV 307 5 11011 5 10 3.02
 XV 0 0 479 5 10 3.55
 XVI 30591 0 94545 5 8 2.61
Patient D:
 I 0 0 334 2.7 10 3.58
 III 0 513500 2535 2 4 3.11
 VII 42477370 0 188 3.3 4 2.38
 XV 16 0 1509 3 3 2.95
Patient E:
 I 5650 57 19920 18 26 5.86
 VII 0 0 37912 7 12 4.61
XII 0 0 0 6 11 4.82
 XIII 0 0 0 6 11 2.84
Patient F:
 I 0 0 0 13 50 5.18
 V 275633 168333 144 3.8 8 4.08
 VI 0 0 312284593 9.6 15 4.48
Patient G:
 I 0 14 329 5.7 30 4.27
 II 1598 53300 58950 14 31 3.77
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In patient B, initially no expression in RNA TNF-α is 
observed, however, the situation changes during the 
3rd monitoring session, after administration of the next 
dose. A relatively increased TNF-α expression – with ref-
erence to patient B – is observed during the 9th and 10th 
monitoring sessions. At the same time, in the case of 
these particular sessions, it was observed that the activ-
ity of the analysed transcript is lower after adalimumab 
administration, when compared with its level before drug 
administration. Generally, apart from rare exceptions, 
TNFR2 expression is at the higher level when compared 
with TNFR1, for which the expression is indeterminable.
A lower TNF-α expression cannot be always observed 
in patient C after administration of the next dose of the 
medicine. Initially, the expression of the discussed gene 
– observed at the relatively low level – increased, which 
is the most visible during the 18th and 9th monitoring ses-
sions, to reach – for some time – the level similar to that 
observed at the beginning of the monitoring process. 
Basically, during the whole observation period, a higher 
quantity of TNFR2 transcripts are noted, when compared 
to TNFR1. 
When analysing the TNF-α expression profile for pa-
tient D, three basic types can be distinguished: the first 
one between the 1st and 6th monitoring sessions, where 
the expression is relatively low, the second between 7th 
and 8th, where the activity level is the highest, though the 
decreasing trend can be noted during the 12th monitoring, 
which is – similarly as during the third stage – the best 
observed during the 14th and 15th monitoring sessions. 
During the highest TNF-α expression, it can be observed 
that TNFR1 expression is greater than TNFR2 expression, 
though the opposite phenomenon is observed during the 
remaining period.
Patient E was monitored for the shortest period 
among all patients. Out of all patients, the TNF-α expres-
sion level was the lowest in that patient. In almost half 
of the monitoring sessions for patient E, the expression 
of analysed gene mRNA is 0 copies/1 μg RNA. Moreover, 
only for that patient no expression was ascertained for 
both receptors (3rd, 10th–13th). In the remaining period 
of the observation, TNFR2 expression was higher than 
TNFR1, as for the other patients.
Clinical and molecular observation for patients F and 
G covered, 6th and 2nd monitoring sessions, respectively, 
which was connected with the patients’ no response to 
medicine. Further treatment is continued in these pa-
tients also basing on the anti-TNF-α therapy (etanercept). 
During the first and last monitoring sessions, no 
TNF-α transcription activity was observed in patient F, 
however, in the remaining period of the observation the 
gene expression was noted. Expression of genes encod-
ing TNFR1 and TNFR2 receptors may also be observed. 
The quantity of mRNA copies of gene TNFR2 was higher 
in comparison to TNFR1. In case of patient G, the obser-
vation period involved two monitoring sessions, during 
which changes in the profiles of three analysed genes 
were noted.
The analysis of TNF-α expression on the proteome 
level in patients (A, B, C, D, E, F) showed total inhibition 
of expression, with the level of TNF-α concentration in 
the patients’ serum of 0 pg/ml. However, patient G had 
the TNF-α protein ascertained at the level of – before 
drug administration – 17 pg/ml, 2 h after drug admin-
istration – 47 pg/ml, during the 2nd monitoring session.
The next part of the experiment described in this 
study involved the analysis of a possible presence of 
statistically significant (p < 0.05) Spearman’s rank cor-
relation rs
 
(due to the fact that there is no regular data 
factorisation) between TNF-α expression and disease 
clinical progression indexes (PASI, BSA, DAS28) for each 
patient and the relationships between the individual in-
dexes. A positive value of the correlation indicates that 
an increased value of one parameter involves an increase 
in another. In turn, a negative value shows that an in-
creased value of one parameter corresponds to a lower 
value of the other analysed parameter. The strongest the 
dependence between the analysed factors, the higher 
value of the correlation.
On the basis of the performed analysis, we observed 
statistically significant correlations between PASI and 
BSA indexes (patient A: rs = 0.6282408 – moderate cor-
relation; patient B: rs = 0.530327 – moderate correlation; 
patient C: rs = 0.806779 – strong correlation; patient E: rs 
= 0.896611 – strong correlation; patient F: rs = 0.942857 
– very strong correlation), between PASI and DAS28 for 
patient C rs = –0.551763 – moderate correlation; for pa-
tient F rs = 0.828571 – very strong correlation).
A statistically significant correlation was observed in 
TNF-α expression and DAS28 (in patient D rs = –0.544785 
– moderate correlation) and between TNF-α expression 
and PASI (in patient F rs = –0.811679 – strong correlation). 
Except for patient G, a positive – moderate to strong – 
correlation was observed between TNF-α expression and 
TNFR1 (patient A rs = 0.764493, patient B rs = 0.452934, 
patient C rs = 0.460081, patient D rs = 0.489495, patient 
E rs = 0.568689, patient F rs = 0.884058). Additionally, 
the correlation between TNF-α expression and TNFR2 
rs = 0.539056 was observed in patient E. 
The last part of the study focused on whether the 
expression of analysed genes: TNF-α, TNFR1, TNFR2 in-
volves an engagement of the epigenetic mechanism of 
gene regulation. To this end, it was determined, in silico, 
which miRNA molecules might potentially post-transcrip-
tionally regulate expression of the analysed genes, using 
the value mirSVR ≤ –0.8 as a cutting point – as the indi-
cator of the potential effect of miRNA on gene expression 
(Table 2).
The in silico analysis, in reference to TNF-α, made it 
possible to observe that its transcription activity may be 
regulated by 39 miRNA molecules, but only 13 miRNAs 
complied with the criterion mirSVR score ≤ –0.8. In turn, 
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TNFR1 expression is regulated by 9 miRNAs, but only 
1 miRNA (hsa-miR-335) complied with the assumed cut-
off criterion for mirSVR score ≤ –0.8. In case of TNFR2, 
it was ascertained that its transcription activity may be 
regulated by 26 miRNAs, but only 1 miRNA (hsa-miR-495) 
complies with the criterion mirSVR score ≤ –0.8 (Table 2).
Discussion
Within the framework of this study, the changes in the 
expression of TNF-α and its receptors TNFR1 and TNFR2 
were analysed at the level of mRNA and proteins in pa-
tients qualified for therapy with the use of an anti-TNF 
medicine: adalimumab. Changes in the expression profile 
of the analysed genes in each patient were analysed in-
dividually and then summarised jointly for each patient, 
with the following clinical parameters: PASI, DAS28, BSA, 
enabling the phenotypic assessment of the patients. 
Personalisation of therapy and individual treatment 
of each patient constitute important and essential is-
sues. The answer to this aspect of diagnostics and treat-
ment is the ‘4P medicine’ – predictive, personalized, pre-
ventive and participatory medicine [17]. Consequently, 
despite the fact all patients received the same medicine, 
in the same dose and were monitored at the identical 
time intervals, in the authors’ opinion, the response to 
the applied treatment should be analysed individually. 
Personalisation of medicine increases the number of 
therapeutic strategies and makes it possible to decrease 
the number of undesirable effects [13, 18–20]. In this 
respect, understanding of molecular aspects of a given 
disease, a response to treatment, knowing and under-
standing of mechanisms relating to response to applied 
pharmacotherapy become important issues.
With reference to the analysis of changes in the tran-
scription activity of TNF-α in patients A-D, basically, it 
was observed that three periods can be distinguished 
during the monitoring of the efficacy of the therapy: 
a relatively low level of expression of the analysed gene, 
a sudden and relatively increased expression, followed by 
a reduced expression. All 4 patients show a little TNF-α 
expression in the initial period of molecular monitoring 
and not very large expression between the individual pe-
riods of observation. Next, an increased expression can 
be observed that lasts for some time during treatment 
observation, only to proceed to the reduced expression 
of the gene encoding TNF-α, compared to the observed 
level. Moreover, during the second stage of the observa-
tion, during the increased TNF-α expression, it was noted 
that TNFR1 expression is higher than TNFR2 expression, 
which is an opposite situation to the one observed at 
the lower level of TNF-α, where the transcription activ-
ity of TNFR1 is lower than TNFR2 expression. In the first 
and last periods of monitoring, the efficacy of therapy, 
TNFR1 expression is observed at the level of 0 copies/1 μg 
RNA or on the similar level. TNFR1 is expressed through 
the majority of nucleated cells and, due to its embedded 
death domain, it participates mainly in the apoptosis of 
cells, whereas TNFR2 expression is observed only on the 
surface of specific cells and it is engaged mainly in the 
induction of T lymphocyte proliferation [21, 22]. An in-
creased TNF-α expression observed by us, accompanied 
by an increased number of TNFR1 transcript copies may 
suggest an escalation of proapoptotic processes, being 
the consequence of the lost response of cells to the anti-
TNF medicine. On the other hand, it should be taken into 
account that intensified TNF-α secretion may not nec-
essarily be triggered by the occurring lost response to 
the drug, but it may be a result of an interferon-γ effect 
(IFN-γ) [23], which intensifies TNF-α secretion as well as 
induces receptor expression for TNF-α [24, 25].
A different expression profile is present in patient E 
– the highest TNF-α expression is observed at the begin-
ning of the molecular treatment, then, during next stages 
of the observation, the expression is relatively low (when 
compared with that observed at the very beginning) 
or amounts to 0 copies/1 μg RNA. Moreover, patient E 
shows a different profile of TNFR1 and TNFR2 expression, 
compared with the other 4 patients. In the vast majority, 
the expression profile remains at the level of 0 copies 
RNA/1 μg RNA.
In turn, patients F and G lost their response to treat-
ment after some time following its commencement. 
These patients show, clinically, relatively low changes in 
the values of parameters describing intensity and ad-
vancement of changes (PASI, BSA, DAS28) and gradually 
Table 2. A list of miRNAs potentially regulating the 
expression of genes: TNF-α, TNFR1, TNFR2 (microrna.org). 
The value criterion mirSVR ≤ –0.8



















Advances in Dermatology and Allergology 5, October/2020742
D. Wcisło-Dziadecka, B. Grabarek, C. Kruszniewska-Rajs, A. Swinarew, K. Jasik, B. Rozwadowska, A. Kaźmierczak
increasing values of the said parameters. Moreover, the 
TNF-α expression in 1 patient was observed not only at 
the transcriptome level, but also at the proteome level. 
Although at the moment of making a decision to dis-
continue the anti-TNF therapy in patient F, the cytokine 
expression level amounts to zero, yet in the previous 
monitoring periods TNF-α expression is observed, which 
seems to confirm that molecular changes precede the 
phenotypic changes [13].
Individual differences in the expression of analysed 
phenotypes in patients subject to the same pharmaco-
therapy constitutes another premise for a personalised 
treatment and an individual approach towards each pa-
tient. Moreover, one should not forget about the individ-
ual variability, a various speed of drug metabolization by 
individual patients [26, 27]. During the studies conducted 
by Czarnecka et al., a higher percentage of persons clas-
sified as ‘quick metabolizers’ was observed among psori-
atic patients (common psoriasis). The researches indicate 
a higher risk of disease development (OR = 1.22) in quick 
metabolizers, when compared with persons with a slow 
and moderate CYP2D6 genotype [28]. One should also 
take into account the possible presence of antibodies di-
rected against adalimumab [29–31]. The possible occur-
rence of the aforementioned regularities may be linked 
with the fact that we have observed no similar, perma-
nent level of TNF-α expression between the individual 
periods of molecular and clinical parameters evaluation. 
It is visible with regard to 1 patient, but the differences of 
such type can also be observed between the individual 
patients.
The efficacy of therapy with the use of adalimumab 
is also confirmed by the data from other centres, which 
also emphasise the immunogenicity of the medicine in 
comparison with other drugs from the anti-TNF blockers 
group [16, 32, 33]. In our studies, it may also be observed 
that TNF-α expression at the mRNA level often remains 
at the low, frequently zero level, relatively after an admin-
istration of just a few doses of the medicine (monitoring 
commencement). Then, as it was already mentioned, 
the number of transcript copies increase, however, the 
prolonged period of drug administration leads to a lower 
expression, because TNF-α is bound and neutralised by 
adalimumab. Changes in the receptor expression profiles 
are observed at that time, which may result from the fact 
that there is no cytokine which could bind with receptors 
and initiate the signal cascade. 
The efficacy of the anti-TNF-α therapy is reflected by 
the fact that we observed lower TNF-α transcription ac-
tivity in patients treated with adalimumab than in the 
control group. Studies conducted by Shveta et al. confirm 
the TNF-α role in psoriasis pathogenesis and, when com-
pared with our own studies, they confirm the efficacy of 
an anti-TNF medicine therapy. They observed a higher 
level of TNF-α in the group of psoriatic patients before 
treatment when compared with healthy persons. During 
the therapy with the use of coal tar (6%) + dithranol + 
salicylic acid (3%), these researchers observed lower con-
centrations of TNF-α proteins in patients [34]. 
In our work, on the basis of the statistical analysis 
performed, we proved the correlation between TNF-α 
expression, PASI and BSA in 2 patients. Both correla-
tions were negative, which means that increased TNF-α 
should correspond to expected decreased values of the 
said clinical indexes. Our observations vary from those 
of Shveta et al. [34], who observed in psoriatic patients, 
following their therapy, lower PASI values and TNF-α 
concentrations. Nevertheless, one should bear in mind 
that a different form of therapy was used and that the 
PASI values in the said paper were compared with TNF-α 
expression at the proteome level. In turn, Serefican et 
al. also ascertained a higher level of TNF-α expression 
in the group of psoriatic patients, when compared with 
the control group and observed a statistically significant 
positive correlation between TNF-α expression and PASI. 
However, one should take into account that the analysis 
of cytokine expression was made at the protein level and 
that the patients were not then subject to any anti-pso-
riasis therapy [35]. Consequently, the fact that we noted 
a negative regulation may indicate the complex mecha-
nism of adalimumab action.
In addition, the strength of the correlation remains 
within the range from moderate to strong. Moreover, sta-
tistically significant correlations were observed between 
PASI and BSA values as well as between PASI and DAS28, 
where the correlation was not lower than moderate and 
the direction of changes – positive. It would confirm the 
usefulness of the afore-mentioned parameters to ex-
amine and analyse the degree of lesion advancement 
in psoriatic patients. The correlation between the TNF-α 
and TNFR1 expression profiles were also noted (in 6 pa-
tients) and between TNF-α and TNFR2 (in 1 patient).
The fact that no TNF-α expression was observed at 
the proteome level (0 pg/ml), while it was observed at 
the transcript level made the authors of this publication 
evaluate the epigenetic mechanism of gene expression. 
The post-transcriptional mechanism of the gene expres-
sion regulation is based on RNA interference, that is why 
miRNAs play a crucial role in it [7, 8]. Basing on the bioin-
formatic databases microrna.org, the search was made 
whether, and – if so – which miRNAs are potentially ca-
pable of regulating TNF-α, TNFR1, TNFR2 expressions, 
and – consequently – inhibiting the TNF-α expression at 
the protein level. 
The occurrence of TNF-α expression at the protein 
level was observed only in 1 patient treated with adalim-
umab, who was classified to change his treatment strat-
egy because of his lost response to therapy. Two hours 
after the administration of another drug dose, a higher 
concentration of protein was observed in this patient 
than before the anti-TNF medicine administration, what 
was also reflected at the transcriptome level.
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The observed expression of TNF-α at the protein 
level in one of the patients who lost their response to 
the therapy may also suggest the effect of adalimumab 
also on the post-transcriptional stage of gene expres-
sion regulation. However, the authors of the publication 
hereto cautiously formulate and generalise such kind of 
conclusions, due to the relatively small group covered by 
the study and its low diversification.
Though the miRNAs for which the values of mirS-
VR ≤ –0.1 are capable of interacting with mRNA of the 
gene, leading to expression inhibition [36], in this study, 
however, only those miRNAs were observed carefully, 
for which the value of mirSVR ≤ –0.8. The use of such 
strict selection criteria made it possible to determine 
only those miRNAs, which may the most likely poten-
tially negatively regulate expression of the analysed 
genes. When using the cut-off criterion, it was noted that 
13 out of 39 miRNAs may regulate TNF-α expression: 
hsa-miR-599, hsa-miR-130a, hsa-miR-130b, hsa-miR-454, 
hsa-miR-301a, hsa-miR-301b, hsa-miR-19b, hsa-miR-19a, 
hsa-miR-181a, hsa-miR-181b, hsa-miR-181c, hsa-miR-181d, 
hsa-miR-150 and one molecule for TNFR1: hsa-miR-335 
and TNFR2: hsa-miR-495. Consequently, it seems that 
an important issue which would make it possible to un-
derstand better the changes in the TNF-α expression 
during the therapy with the use of an anti-TNF medi-
cine (adalimumab) in patients is to consider the role of 
the post-transcriptional mechanism of gene expression 
regulation by miRNAs [37–39]. The role of miRNA-130a, 
miR-454-3p in the negative regulation of TNF-α expres-
sion was confirmed by Huang et al., which coincides 
with our observation at the in silico level [40]. Moreover, 
it was observed that miR-301a (miRSVR -1.1996), belong-
ing to the family of miR-130, engaged in the process of 
cell migration has got great potential to regulate TNF-α 
expression [41]. The role of hsa-miR-130a in proinflam-
matory processes and its effect on the expression pro-
file of proinflammatory cytokines was confirmed by He 
et al., who observed its significant role in the intestine 
mucous membrane inflammation. The said authors state 
that the inhibition effect of the discussed molecule may 
constitute a new therapeutic strategy [42]. Basing on the 
bioinformatic tool used to search for miRNAs potentially 
regulating gene expression, it may be observed that hsa-
miR19a and hsa-miR19b molecules are engaged in the 
regulation of the TNF-α expression. The observations 
performed by us in silico coincide with those obtained 
by other groups of researchers, who described a lower 
expression of those molecules in patients with rheuma-
toid arthritis [43], and indicate their role in shaping the 
TNF-α expression profile [44, 45]. The last large group of 
miRNAs involving the regulation of transcriptional activ-
ity of TNF-α is composed by 4 molecules belonging to the 
hsa-miR-181 family. Mir-181a is perceived as the marker 
of inflammatory response, the expression of which is 
correlated, among others, with TNF-α expression [46]. 
Moreover, hsa-miR-181a plays an important role in differ-
entiating and maturing of the immunologic system cells 
[47]. In turn, mir-181 is described as a molecule playing 
a significant role in proapoptotic activity TNF-α [48]. Two 
miRNAs were identified in this paper, which the most 
likely participate in the regulation of expression TNFR1 
receptors: hsa-miR-335, TNFR2: hsa-miR-495. Changes 
in the receptor expression profiles observed during the 
adalimumab therapy may also result from the changes in 
the expression profiles of the mentioned miRNAs during 
the anti-TNF therapy. The role of mir-335 in the preserva-
tion and maintenance of body homeostasis [49] and the 
role of tmiR-495 as a molecule participating in the immu-
nologic response and apoptosis are emphasised [45, 50]. 
For that reason, the observed changes in the expression 
of TNFR1 and TNFR2, in correlation with the mRNA TNF-α 
activity may indicate that the body strives to reach the 
balance and homeostasis.
Conclusions
The evaluation of the efficacy of the anti-TNF therapy 
with the use of molecular biology methods constitute 
an increasingly important tool that makes it possible 
to monitor the effects of therapy [51]. Moreover, the re-
sults obtained in our work also show that an individual 
variability must be taken into account when monitoring 
therapeutic effects at the transcriptome and proteome 
level in patients treated with adalimumab, as well as un-
derline the essence of the epigenetic mechanism of RNA 
interference by miRNAs. The obtained results indicate an 
important role of introducing the changes in the cytokine 
expression profile as a supplementary diagnostic marker.
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